43 related articles for article (PubMed ID: 17452255)
1. Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
Okabe S; Moriyama M; Gotoh A
Leuk Lymphoma; 2024 May; 65(5):696-699. PubMed ID: 38300854
[No Abstract] [Full Text] [Related]
2. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Eide CA; Adrian LT; Tyner JW; Mac Partlin M; Anderson DJ; Wise SC; Smith BD; Petillo PA; Flynn DL; Deininger MW; O'Hare T; Druker BJ
Cancer Res; 2011 May; 71(9):3189-95. PubMed ID: 21505103
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
4. Isodicentric Philadelphia chromosome in accelerated phase of chronic myeloid leukemia.
Pernice F; Squadrito G; Saitta A; Mazza G; Musolino C
Cancer Genet Cytogenet; 1993 Apr; 66(2):113-6. PubMed ID: 8500097
[TBL] [Abstract][Full Text] [Related]
5. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.
Bixby D; Talpaz M
Leukemia; 2011 Jan; 25(1):7-22. PubMed ID: 21102425
[TBL] [Abstract][Full Text] [Related]
6. Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia.
Li Q; Lin XJ; Chen H; Gong J; Li Z; Chen XN
Oncol Lett; 2018 Apr; 15(4):4599-4603. PubMed ID: 29541231
[TBL] [Abstract][Full Text] [Related]
7. Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML).
Loo E; Bansal P; Cherukuri D; Arana Yi C
Clin Case Rep; 2016 Jan; 4(1):43-5. PubMed ID: 26783434
[TBL] [Abstract][Full Text] [Related]
8. Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Al-Achkar W; Wafa A; Moassass F; Klein E; Liehr T
Oncol Lett; 2013 May; 5(5):1579-1582. PubMed ID: 23761821
[TBL] [Abstract][Full Text] [Related]
9. Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.
Virgili A; Nacheva EP
Mol Cytogenet; 2010 Sep; 3():15. PubMed ID: 20809971
[TBL] [Abstract][Full Text] [Related]
10. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
11. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
12. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
14. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
15. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
